An open label randomized controlled trial on the preemptive risedronate intervention for renal transplant patients receiving glucocorticoid

INTERVENTION: Active vitamin D alone (2 year) Active vitamin D + risedronate (2 year) CONDITION: Bone disease in renal transplant patients receiving glucocorticoid PRIMARY OUTCOME: Change in bone mineral density and bone turnover markers at two‐year interval SECONDARY OUTCOME: Ca, iP, PTH, and indices of renal function. Safety. INCLUSION CRITERIA: Renal transplant patients receiving glucocorticoid treatment (2.5 mg/day of prednisolone equivalent or greater) with low bone mineral density (T‐score at the lumbar spine <= ‐1.0) and stable renal function (serum creatinine <= 2.0 mg/dL).